Watch the Video
Focused on your needs, our specialists provide appropriate support for precision bioanalysis, and a full range of research services for a wide range of study types — working with you to accelerate development, meet your milestones, and ensure compliant, on-time regulatory submissions for your drug candidates.
Bring your talents and forward-thinking approach to Altasciences and help us develop medicines for those who need them, faster. We have a number of opportunities for you to explore.
Related Press Release
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions
From formulation development, phase I through commercial manufacturing, and ICH stability testing
Related Press Release
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
NEWS
Working as a flexible, attentive extension of your team, we offer all you need to move your molecule forward.
